Roche agreed to license Simcere Zaiming’s preclinical trispecific T-cell engager SIM-0660 in a deal worth up to $1.53 billion, with a $75 million upfront payment. The asset targets CD79a/CD19 on B cells and CD3 on T cells, aiming to drive T-cell mediated killing while limiting cytokine-release risk observed in earlier generations of T-cell engager platforms. Under the terms, Roche obtains exclusive global rights to develop, manufacture and commercialize SIM-0660, while Simcere is eligible for development, regulatory, and commercial milestones. The molecule was described as being aimed at B-cell-mediated diseases including lymphoma and autoimmune conditions. The agreement signals continued big-pharma interest in next-generation bispecific and trispecific engagement strategies, particularly where platforms emphasize selectivity to improve safety.